CLAIMS

1. An extracellular vesicle (EV) modified to comprise at least one albumin binding domain (ABD) present on the surface of the EV.

2. An EV according to claim 1, wherein the ABD forms part of a fusion protein with an EV protein, optionally wherein the EV protein is a transmembrane EV protein or an EV protein associated with the outer surface of the EV membrane.

3. An EV according to claim 2, wherein the ABD is engineered into an extravesicular loop of a multi-pass transmembrane protein, optionally wherein the multi-pass transmembrane protein is a tetraspanin.

4. An EV according to claim 2 or 3, wherein the EV protein is selected from the group consisting of: CD63, CD81, CD9, CD82, CD44, CD47, CD55, LAMP2B, ICAMs and ARRDC1, as well as derivatives, domains, variants, mutants, or regions thereof.

5. An EV according to any one of the preceding claims, wherein the EV comprises more than one ABD.

6. An EV according to any one of claims 2 to 5, wherein more than one ABD is present in the same fusion protein.

7. An EV according to any one of the preceding claims, wherein the EV is further loaded with a therapeutic cargo, optionally wherein the therapeutic cargo is a protein, nucleic acid, virus, viral genome, antigen or small molecule.

8. An EV according to claim 7, wherein the therapeutic cargo is selected from the group consisting of: a nucleic acid, optionally an RNA molecule, a DNA molecule or a mixmer, mRNA, an antisense or splice-switching oligonucleotide, siRNA, shRNA, miRNA, plasmid DNA (pDNA), a supercoiled or unsupercoiled plasmid, or a mini-circle; a peptide or protein, optionally a transporter, enzyme, receptor (optionally a decoy receptor), membrane protein, cytokine, antigen or

neoantigen, ribonuclear protein, nucleic acid binding protein, antibody, nanobody or an antibody fragment; an antibody-drug conjugate; a small molecule drug; gene editing technology, optionally CRISPR-Cas9, a TALEN, meganuclease; or a vesicle-based cargo, optionally a virus, optionally an AAV or a lentivirus.

9. An EV according to claims 7 or 8, wherein the therapeutic cargo is present on the inside of the EV, on the outside of the EV and/or in the membrane of the EV.

10. An EV according to any one of claims 7 to 9, wherein the therapeutic cargo forms part of the EV protein-ABD fusion protein.

11. An EV according to any one of the preceding claims, wherein the EV further comprises a targeting moiety.

12. An EV according to claim 11, wherein the targeting moiety forms part of the ABD fusion protein.

13. A method for producing an EV according to any one of the preceding claims, comprising: (i) introducing into an EV-producing cell at least one polynucleotide construct encoding an ABD-EV protein fusion construct; and (ii) expressing said construct in the EV-producing cell, thereby generating an EV comprising ABD present on the surface of the EV.

14. A pharmaceutical composition comprising at least one EV according to any one of claims 1 to 12 and a pharmaceutically acceptable excipient or carrier.

15. An EV according to any one of claims 1 to 12, and/or a pharmaceutical composition according to claim 14, for use in medicine.